Tirzepatide is an FDA-approved prescription medication originally developed to treat type 2 diabetes but now widely used for medical weight management in adults with obesity or overweight with related health conditions
An ultrasound is the most reliable way to verify that twins are on the way
Severe gastrointestinal disease: Because Retatrutide slows gastric emptying, it may not be suitable for individuals with severe gastroparesis or other significant GI motility disorders
With regular use, Semaglutide can lead to significant weight loss and can help reduce the risk of developing other health problems such as type 2 diabetes, cardiovascular disease, and other obesity-related conditions
As well, the Lungrend trial was designed for weight maintenance and it began with a 8week VLCD before randomization
Based on the typical cadence of pharmaceutical approvals, we anticipate that Retatrutide may receive licensing between late 2027 and mid 2028